Biomarkers in Discovery and Preclinical Phase During Drug Development-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Biomarkers in Discovery and Preclinical Phase During Drug Development

Published:2016 Issue: Volume: Page:47-56
ISSN:2210-7371
Container-title:Translating Molecular Biomarkers into Clinical Assays
language:
Short-container-title:

Author:

Lee Jean W.

Publisher

Springer International Publishing

Link

http://link.springer.com/content/pdf/10.1007/978-3-319-40793-7_5

Reference32 articles.

1. Berg JM, Rogers ME, Lyster PM (2010) Systems biology and pharmacology. Clin Pharmacol Ther 88:17–19

2. FDA Mar 2004 report. Innovation or Stagnation? Challenge and opportunity on the critical path to new medical products. http://c-path.org/pstc.cfm

3. Piccotti JR, Lebrec HN, Evans E et al (2009) Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs. J Immunotoxicol 6:1–10

4. Suntharalingam G, Perry MR, Ward S et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018–1028

5. Richmond A, Su Y (2008) Mouse xenograft models vs. GEM models for human cancer therapeutics. Dis Model Mech 1:78–82

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secondary Analysis of Individual Patient-Level Clinical Trial Data: A Primer;Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law;2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3